Novo Nordisk Hunts for Deals After Losing Metsera to Pfizer
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.
/ 41 items
#PFE↓
Moderna Rises as CEO Eyes European Market and Flu-Covid Vaccine
Moderna stock jumps 14%, driven by European expansion plans and a new flu-Covid combo vaccine aiming for 2026 approval.
Tempus AI Hits Major Milestone with $1.1 Billion in Contracts
Tempus AI achieves record $1.1 billion in total contract value, partners with 70+ pharmaceutical companies, and reports 31% revenue growth in 2025.
Patient Death in Pfizer's Hympavzi Trial Raises Safety Questions for Hemophilia Treatment
Pfizer investigates death of hemophilia patient in Hympavzi trial after thrombotic stroke. Company says no expected safety impact for approved use.
Novo Nordisk Wins FDA Approval for Wegovy Weight-Loss Pill, Beating Lilly to Market
Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.
Pfizer Forecasts Flat Growth in 2026 Amid Pipeline Refresh
Pfizer projects $59.5-62.5B revenue for 2026 with minimal growth as it invests in obesity drugs and cuts costs while COVID sales decline and key patents expire.